Version 2.1.1.0 |
![]() |
![]() ![]() ![]() |
Abstract
Grant Number: 4R44HL072671-02 PI Name: NELSON, RANDALL W. PI Email: rnelson@intrinsicbio.com PI Title: PRESIDENT & CEO Project Title: Mass Spectrometric Immunoassay of Apolipoproteins Abstract: DESCRIPTION (provided by applicant): Proposed in this Fast Track Phase I/Phase II proposal is the development of mass spectrometric immunoassays (MSIA) targeting apolipoproteins in human blood. Assays, utilizing antibody-derivatized affinity pipettes and MALDI-TOF mass spectrometry, will be developed for Apo-A, -C, -D, -E, -H and -J. These assays will have general use in studies investigating the quantitative modulation of, and point mutations and posttranslational modifications present in, the apolipoproteins. Phase I research will address the Specific Aim of optimizing affinity pipette chemistries for apolipoproteins. By reaching the Phase I milestone of high reproducibility, low non-specific binding qualitative assays (for the apolipoproteins when analyzed from small volumes (< 50 uL) of human blood), we will proceed into Phase II research. Phase II objectives include: 1) The use of enzymatically-active MALDI-TOF MS targets in conjunction with MSIA for structural characterization of the apolipoproteins, 2) The incorporation of quantitative methodologies into the assays, and 3) The development of a MSIA assay for common ApoE phenotypes. The final objective of the program is the development of kits and low-cost analytical platforms for the high-throughput analysis of apolipoproteins. Upon supply to the public, the approach will find initial applications in proteomic investigations linking protein variants with disease and potential long-term applications as phenotyping assay for use in clinical/diagnostic or drug administration applications.
Thesaurus Terms:
apolipoprotein, immunologic assay /test, matrix assisted laser desorption ionization, method development
apolipoprotein E, point mutation, posttranslational modification, protein binding, proteomics
biotechnology, clinical research, human subject
Institution: INTRINSIC BIOPROBES, INC. 625 S SMITH RD, STE 22 TEMPE, AZ 85281 Fiscal Year: 2003 Department: Project Start: 17-JAN-2003 Project End: 30-JUN-2005 ICD: NATIONAL HEART, LUNG, AND BLOOD INSTITUTE IRG: ZRG1
![]()
![]()
![]()